Optimer’s Dificid Gets Medicare Payment “Add-On” For Hospital Patients
This article was originally published in The Pink Sheet Daily
In a rare application of its Medicare “new technology add-on payments” policy to drugs, the Centers for Medicare and Medicaid Services announced it will supplement reimbursement to hospitals for the oral antibiotic Deficid and methotrexate toxicity antidote Voraxaze.
You may also be interested in...
CMS agrees to provide new technology add-on payments for Amgen’s cancer drug for acute lymphoblastic leukemia after the company documents Blincyto’s uniqueness and its advantages over existing treatments.
CMS disappointed stakeholders looking for antibiotic payment incentives from Medicare with two recent decisions. One was to withhold new technology add-on payments from Dalvance and the other to allow existing NTAP benefits for Dificid to expire.
Company is banking on its single-dose treatment course to propel it over competitors in a crowded generic and branded space, but this may involve major changes in treatment practice, analysts say.